Drug
D0416 | Benoxaprofen
M
M01AE06 Benoxaprofen
[M01AE] Propionic acid derivatives
[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
[M] Musculoskeletal system
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| OXYGEN CONSUMPTION RATE (OCR) | 30 μM | 2 minutes | human | HepG2 | Measurement of ECAR | decrease | EC50 | 7 |
| ELECTRON TRANSPORT CHAIN | 50 μM | bovine | heart mitochondria | Measurement of complex I activity | Negative | p < 0.05 | 3 | |
| ELECTRON TRANSPORT CHAIN | 50 μM | bovine | heart mitochondria | Measurement of complex II + III activity | Negative | p < 0.05 | 3 | |
| ELECTRON TRANSPORT CHAIN | 50 μM | bovine | heart mitochondria | Measurement of complex II + III activity | Negative | p < 0.05 | 3 | |
| ELECTRON TRANSPORT CHAIN | 50 μM | bovine | heart mitochondria | Measurement of complex IV activity | Negative | p < 0.05 | 3 | |
| ELECTRON TRANSPORT CHAIN | 50 μM | bovine | heart mitochondria | Measurement of complex V activity | Negative | p < 0.05 | 3 | |
| ECAR | > 100 μM | 2 minutes | human | HepG2 | Measurement of ECAR | increase | EC50 | 7 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 50 μM | bovine | heart mitochondria | Measurement of complex I activity | Negative | p < 0.05 | 3 | |
| Succinate dehydrogenase | 50 μM | bovine | heart mitochondria | Measurement of complex II + III activity | Negative | p < 0.05 | 3 | |
| Quinol--cytochrome-c reductase | 50 μM | bovine | heart mitochondria | Measurement of complex II + III activity | Negative | p < 0.05 | 3 | |
| Cytochrome c oxidase | 50 μM | bovine | heart mitochondria | Measurement of complex IV activity | Negative | p < 0.05 | 3 | |
| ATP synthase | 50 μM | bovine | heart mitochondria | Measurement of complex V activity | Negative | p < 0.05 | 3 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Danger |
Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral] H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P273, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | oral | 780mg/kg/13W- (780mg/kg) | endocrine: gynecomastia | British Medical Journal. Vol. 284, Pg. 1365, 1982. |
| women | LDLo | oral | 780mg/kg/65D- (780mg/kg) | liver: "jaundice, other or unclassified" | Lancet. Vol. 1, Pg. 959, 1982. |
| rat | LD50 | intraperitoneal | 129mg/kg (129mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981. | |
| rat | LD50 | subcutaneous | 121mg/kg (121mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981. | |
| rat | LD50 | oral | 118mg/kg (118mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981. | |
| women | TDLo | oral | 552mg/kg/46D- (552mg/kg) | liver: "jaundice, other or unclassified" | Lancet. Vol. 1, Pg. 959, 1982. |
| mouse | LD50 | oral | 800mg/kg (800mg/kg) | Journal of Medicinal Chemistry. Vol. 18, Pg. 53, 1975. | |
| mouse | LD50 | subcutaneous | 482mg/kg (482mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981. | |
| women | TDLo | oral | 168mg/kg/2W-I (168mg/kg) | Nephron. Vol. 35, Pg. 279, 1983. | |
| mouse | LD50 | intraperitoneal | 398mg/kg (398mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 9, Pg. 4445, 1981. | |
| ( -)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid | ( -)-Benoxaprofen | (+-)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid |
| (+-)-2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid | (+-)-benoxaprofen | (+/-)-2-(4-chlorophenyl)benzoxazole-5-propionic acid |
| (.+/-.)-2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid | (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid | (alphaR)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid |
| (alphaS)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid | 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid | 2-(2-(4-chlorophenyl)benzo[d]oxazol-5-yl)propanoic acid |
| 2-(4-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid | 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid | 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid |
| 2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid | 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid | 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid # |
| 2-[2-(4-chlorophenyl)benzooxazol-5-yl]propanoic acid | 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl, (.+/-.)- | 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-.alpha.-methyl- |
| 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl, (+-)- | 5-Benzoxazoleacetic acid, 2-(4-chlorophenyl)-alpha-methyl- | 51234-28-7 |
| 67434-14-4 | API0007668 | BDBM50088388 |
| BRN 1085080 | Benoxaprofen | Benoxaprofen (USAN/INN) |
| Benoxaprofen [USAN:INN:BAN] | Benoxaprofene | Benoxaprofene [INN-French] |
| Benoxaprofeno | Benoxaprofeno [INN-Spanish] | Benoxaprofenum |
| Benoxaprofenum [INN-Latin] | C16H12ClNO3 | CHEBI:76114 |
| CHEMBL340978 | CTK2F8145 | Compound 90459 |
| Coxigon | D03080 | DA-05331 |
| DB04812 | DTXSID4022650 | EINECS 257-069-7 |
| EINECS 266-692-3 | FT-0662523 | Inflamid |
| LRCL 3794 | LS-42081 | Lilly 90459 |
| MITFXPHMIHQXPI-UHFFFAOYSA-N | NSC 299582 | NSC-299582 |
| NSC299582 | Opren | Oraflex |
| Oraflex (TN) | Q420082 | SC-20578 |
| SCHEMBL24413 | Uniprofen | dl-Benoxaprofen |
| DrugBank Name | Benoxaprofen |
| DrugBank | DB04812 |
| CAS Number | 51234-28-7, 67434-14-4 |
| PubChem Compound | 39941 |
| KEGG Drug | D03080 |
| PubChem.Substance | 46508496 |
| ChEBI | 76114 |
| PharmGKB | PA166049178 |
| ChemSpider | 36518 |
| BindingDB | 50088388.0 |
| TTD | DCL000338 |
| Wikipedia | Benoxaprofen |